AbbVie Inc. (ABBV)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NYSE
Market cap: $466.55B
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Latest financial period: June 30, 2026
Filed with the SEC: August 3, 2026
Estimated earnings date: October 30, 2026
Profit #309 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | 19.1% | 16.0% | 15.6% | 14.3% |
Growth #820 of 1484 companies
Payout #1038 of 1484 companies
Safety #1179 of 1484 companies
Price #1027 of 1484 companies
